February 17, 2022
The merger of Cerba Research and Viroclinics-DDL
Together, transforming diagnostics for clinical trials.
After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).
We are united in our shared expertise, values, and mission for improving people’s lives by enabling clinical trials for drug development across the world. Our ambition is to build the future of healthcare together with our people and customers.
Expanding and transforming our diagnostic solutions for clinical trials while reducing risk for our customers
With our enhanced portfolio of integrated specialty testing services and assay development in multiple therapeutic areas, and the latest technology available in flow cytometry, immunohistochemistry, NGS, and immunoassay, we offer a more comprehensive portfolio of solutions and capabilities at every stage of clinical trials.
Our portfolio of scientific and technical expertise combined with our global capabilities, vast databases of patient data and samples, and best-in-class logistics remove the uncertainty from sample management, reduce risk, and enable the accuracy and acceleration of your drug development projects from start to finish.
Access to exceptional scientific and technical teams in multiple treatment areas for drug and vaccine development
With our unparalleled scientific expertise, the fast-expanding portfolio of therapeutic areas includes a focus on Oncology and Immuno-Oncology, Metabolic Diseases, Virology and other Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurology and Rare Diseases.
Your global partner for specialised laboratories and patient data
Our customers will continue to access industry-leading scientists and technical teams with our cutting-edge specialist laboratory network of over 1000 labs including, BSL2 and BSL3 labs in Europe, the Americas, Africa, Asia and Australia, as well as data from over 45 million patients across five continents, removing the uncertainty from accessing patient data.
Best-in-class logistics services
This merger makes secure sample management and transportation at a global scale even more effective. Our global in-house logistics capability will facilitate a safe and guaranteed sample management process, ensuring that even the most fragile and unstable samples are transported without compromising their integrity and safety. Every sample counts.
Business as usual
Both Cerba Research and Viroclinics-DDL take pride in their project management and customer service capabilities and skills. Now, as one company, our customer-centric approaches are strengthened even more. For our customers, there will be no disruptions. It is business as usual. Both companies will eventually unite under the Cerba Research brand, however over the coming weeks, Viroclinics DDL will be known as a Cerba Research company, reflected in the updated logo.